Sanofi has completed the acquisition of DR-0201 from Dren Bio, now renamed SAR448501, to enhance its immunology pipeline. This bispecific myeloid ...

Sanofi completes acquisition of DR-0201, a bispecific myeloid cell engager from Dren Bio: Paris Wednesday, May 28, 2025, 09:00 Hrs [IST] Sanofi announces the completion of its acq ...

Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc ...

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private c ...

ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed preclinical ...

A preclinical research showing scientists are a step closer to finding new ways to target leukaemia, one of the most ...

Scientists have discovered "barcodes" within DNA that reveal how blood ages, potentially paving the way for preventing ...

Without PSPC1, myeloid cell differentiation resumed ... 1, a transcription factor essential for blood and immune cell development. This interaction activated tumor-promoting genes, including ...

Therapeutic efforts in acute myeloid leukemia (AML ... how specific genetic mutations disrupt the normal development of blood cells, yet a complete understanding of how these mutations shape ...